Article Sidebar

PDF
Date Published: 25/12/2023
Online Published: 25/12/2023
Abstract Views: 50
Views PDF: 27
DOI: https://doi.org/10.58490/ctump.2023i69.1996
Issue
No. 69 (2023)
Section
Article
How to Cite
Nguyen, N. N., Huynh , M. G., & Mai, H. N. T. (2023). IMMUNE RESPONSE AFTER FOURTH DOSE OF COVID-19 VACCINE IN PATIENTS WITH END-STAGE RENAL DISEASE ≥60 YEARS OLD. Cantho Journal of Medicine and Pharmacy, 69, 230-237. https://doi.org/10.58490/ctump.2023i69.1996

IMMUNE RESPONSE AFTER FOURTH DOSE OF COVID-19 VACCINE IN PATIENTS WITH END-STAGE RENAL DISEASE ≥60 YEARS OLD

Nhu Nghia Nguyen1,, Minh Giau Huynh 2, Huynh Ngoc Tan Mai1
1 Can Tho University of Medicine and Phamarcy
2 Giong Rieng General Hospital

Main Article Content

Abstract

Background: The Covid-19 pandemic seriously affected the health of people around the world. Vaccination against Covid-19 is a safe and reliable way to generate antibodies against SARSCoV-2 virus, which helps to reduce morbidity and risk of severe illness. Vietnam has administered fourth doses of Covid-19 vaccine to people, but there have not been many studies on Covid-19 antibody levels, especially in patients with chronic kidney disease.. Objectives: To evaluate levels of antibodies after four weeks and six months of 4th dose of Covid-19 vaccine and some related factors in chronic kidney disease patients ≥60 years old undergoing hemodialysis. Materials and methods: A cross-sectional descriptive study with longitudinal follow-up 33 patients ≥60 years old and 30 patients <60 years old with end-stage renal disease (ESRD) undergoing hemodialysis at Can


Tho General hospital, after 4th dose of Covid-19 vaccine, from July 2022 to April 2023. Results:


The mean age of the study group was 66.8±6.5 years old, the dialysis vintage was 4.7 years. Antibody levels after four weeks of injection 4 were 12723.0 [6759.0-16861.0] (AU/mL), after six months decreased to 5628.0 [2976.0-9733.0] (AU/mL), p<0.05. All patients had an immune response after receiving 4th dose of Covid-19 vaccine. After 6 months, 87.9% of patients ≥60 years old had a decrease in antibody levels. Patients with more comorbidities had lower antibody levels than those with fewer comorbidities. Conclusions: Patients with ESRD ≥60 years old had a good immune response after receiving 4th dose of Covid-19 vaccine. History of multiple comorbidities was associated with significant decline in antibody levels after 6 months.

Article Details

Keywords

Covid-19, ESRD, vaccine, Can Tho

References

1. Hoàng Lê Trung Hiếu, Châu Ngọc Minh, Trần Thị Thu Vân, Ngô Việt Thảo, Nguyễn Trần Mỹ Phương và cộng sự. Đặc điểm sinh kháng thể trung hòa kháng vùng liên kết thụ thể (RBD) protein gai của SARS-CoV-2 của nhân viên y tế được tiêm ngừa vaccine Covid-19 tại bệnh viện Mỹ Đức. Tạp chí Y Học TP. Hồ Chí Minh. 2022, 26(1), 8-15.
2. Paul M., Sarah G,, Candice L.C., Tina T., Helena E., et al. Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study. The Lancet Regional Health – Europe. 2022. 21, 100478, https://doi.org/10.1016/j.lanepe.2022.100478.
3. Nguyễn Văn Tuấn, Trần Thị Anh Thơ. Khảo sát đặc điểm thiếu máu ở bệnh nhân bệnh thận mạn giai đoạn cuối lọc máu chu kỳ. Tạp chí Y Học Việt Nam. 2021, 503(2), 193-198. https://doi.org/10.51298/vmj.v503i2.799.
4. Clara B., Sergio G.B., Francisco T.S., Juan S., Vicente B.G., et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020, 21(7), 915-918. https://doi.org/10.1016/j.jamda.2020.05.045.
5. Michal C., Noam B., Mayan G., Victoria I., Michal M., et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nature Communications. 2022, 13:7711. https://doi.org/10.1038/s41467-022-35480-2.
6. Tammy H., Aharon B.D., Eytan M., Liraz O., Rebecca H., et al. Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients. Transplantation. 2023, 107(1), 192-203. DOI: 10.1097/TP.0000000000004383.
7. Patrick A., Felix C.K., Karl A.B., Martin G., Eva P., et al. Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients. Viruses. 2022, 14, 2646. https://doi.org/10.3390/v14122646.
8. Borja Q., María J.S., Alberto O., Ron T.G., Alba L., et al. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis. Vaccines. 2022, 10, 1738. https://doi.org/10.3390/vaccines10101738.
9. Ole S.S., Joanne R., Isik S.J., Henrik N., Thomas B., et al. Characteristics associated with serological Covid-19 vaccine response and durability in older population with significant comorbidity: the Danish Nationwide ENFORCE Study. Clinical Microbiology and Infection. 2022, 28, 1126-1133. https://doi.org/10.1016/j.cmi.2022.03.003.
10. Timothy A.B., Hans C.L., Zoe L.L., James R.G., Marcel E.C., et al. Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine ImmuneSerum Samples. JAMA. 2021, 326(9): 868– 869. doi:10.1001/jama.2021.11656.